Healthcare Industry News: Asuragen
News Release - December 14, 2007
Study Shows MammaPrint(R) Breast Cancer Test Provides Benefits to Patients from Personalized Treatment RegimenNew Lancet Oncology publication provides important insights on the use of MammaPrint(R) Breast Cancer Prognosis Test in clinical practice
AMSTERDAM, The Netherlands, Dec. 14 (HSMN NewsFeed) -- New research demonstrates that the MammaPrint® breast cancer prognosis test was successfully implemented in the diagnostic process of breast cancer patients in community hospitals in The Netherlands. MammaPrint® assigned up to one- third of the patients to different risk categories as compared to currently used risk assessment tools. In the majority of these situations, it may lead to a reduction in the use of adjuvant chemotherapy. The findings were published in the December issue of The Lancet Oncology.
"More than 70 percent of patients who have node-negative breast cancer are successfully treated without chemotherapy. Identifying which patients with breast cancer will most likely require adjuvant chemotherapy is an important step in personalizing a patient's treatment regimen, and ensuring that patients aren't receiving unnecessary treatment," said Dr Laura van 't Veer, chief research officer at Agendia, who participated in the study.
According to the results in The Lancet Oncology, adjuvant chemotherapy was advised less often when the patient's prognosis was based on the DUTCH CBO Guidelines -- which are considered the most restrictive -- compared with assessments based on MammaPrint®. For the other guidelines assessed, however, less adjuvant therapy would be given based on the prognosis of MammaPrint®. These results confirm previous findings and validations with the test.
"These data provide important information to patients and physicians that can effectively help guide treatment decisions in community-based hospitals. The prognosis provided by MammaPrint®, together with guidance from clinical guidelines and patients' treatment preferences, are vital tools for physicians caring for breast cancer patients," said Bernhard Sixt, chief executive officer at Agendia.
MammaPrint® laboratory service is the first and only FDA cleared (February 2007) DNA microarray-based 'in vitro diagnostic multivariate index assay' (IVDMIA). MammaPrint® measures the activity of 70 genes, providing information about the likelihood of tumor recurrence. The MammaPrint® test measures the level of expression of each of these genes in a sample of a woman's surgically-removed breast cancer tumor and then uses a specific formula or algorithm to produce a score that determines whether the patient is deemed low risk or high risk for spread of the cancer to another site. The result may help a doctor in planning treatment and appropriate follow-up for a patient when used with other clinical information and laboratory tests. All MammaPrint® tests are conducted in Agendia's CLIA-certified central service laboratory.
Agendia, located in Amsterdam, The Netherlands, is a world leader in gene expression analysis-based diagnostics with three products on the market. The company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling. Agendia was the first company to commercialize a prognostic test -- MammaPrint® -- that predicts the risk of breast cancer recurrence. Agendia maintains close ties with several leading academic centers to develop state of the art diagnostic tests for cancer. Agendia also offers its expertise to pharma companies focusing on development of highly effective personalized drugs in the area of oncology. For more information on Agendia, please visit www.agendia.com.
* RNARetain® is a trademark of Asuragen Inc.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.